GlassScriptPhysician profile
Nikole A Murray
NPI 1255925327
$7,467.80
in general payments reported to CMS, 2019-2025
30 companies · $2,290 in 2025
The $2,290 reported for 2025 was more than what 95% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $573 · 2022: $1,107 · 2023: $1,309 · 2024: $2,189 · 2025: $2,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,405 · Education: $383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,404.54 |
| Education | $383.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,178.36 | 2022-2025 | Tremfya |
| Abbvie INC. | $1,125.37 | 2022-2025 | |
| Galderma Laboratories, L.P. | $779.17 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Ucb, INC. | $673.20 | 2021-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $536.54 | 2023-2025 | Sotyktu |
| Genzyme Corporation | $464.70 | 2022-2025 | |
| Lilly USA, LLC | $464.65 | 2021-2025 | Olumiant, Taltz, Ebglyss |
| Sun Pharmaceutical Industries INC. | $263.33 | 2021-2025 | |
| Incyte Corporation | $241.70 | 2021-2025 | Opzelura, Opzelura |
| Leo Pharma INC. | $240.21 | 2021-2025 | Adbry |
| Novartis Pharmaceuticals Corporation | $227.33 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $174.95 | 2024-2025 | |
| Dermavant Sciences, INC. | $170.51 | 2023-2024 | Vtama |
| Pfizer INC. | $167.18 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $119.19 | 2022-2025 | Libtayo, Dupixent |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $92.55 | 2023-2025 | Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $91.70 | 2021-2025 | Cabtreo, Jublia |
| Revance Therapeutics, INC. | $87.30 | 2024-2025 | Daxxify |
| Organon LLC | $68.20 | 2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $57.91 | 2023-2025 | Zoryve |
| Biofrontera INC. | $47.82 | 2021-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Mayne Pharma Commercial LLC | $32.90 | 2023 | |
| Verrica Pharmaceuticals INC. | $30.01 | 2024 | Ycanth |
| Almirall LLC | $25.54 | 2024 | Klisyri |
| Botanix Sb INC | $23.64 | 2025 | Sofdra |
| Kyowa Kirin, INC. | $23.54 | 2022 | |
| Springworks Therapeutics, INC. | $20.64 | 2025 | Gomekli |
| Convatec INC. | $19.86 | 2025 | |
| Journey Medical Corporation | $12.04 | 2022 | |
| Biowound Solutions, INC. | $7.76 | 2025 | Bio-Connekt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikole Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.